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© 2011 The Japan Society of Histochemistry and Cy- Akt, or protein kinase B, is an important signaling molecule that modulates many cellular
processes such as cell growth, survival, and metabolism. However, the vivo roles and
effectors of Akt in retinal angiogenesis are not explicitly clear. We therefore detected the
expression of Akt using Western blotting or RT-PCR technologies in an animal model of
oxygen-induced retinopathy, and investigated the effects of recombinant Akt on inhibiting
vessels loss and Akt inhibitor on suppressing experimental retinal neovascularization in
this model. We showed that in the hyperoxic phase of oxygen-induced retinopathy, the
expression of Akt was greatly suppressed. In the hypoxic phase, the expression of Akt was
increased dramatically. No significant differences were found in normoxic groups. Compared
with control groups, administration of the recombinant Akt in the first phase of retinopathy
markedly reduced capillary-free areas, while the administration of the Akt inhibitor in the
second phase of retinopathy significantly decreased retinal neovascularization but capillary-
free areas. These results indicate that Akt play a critical role in the pathological process
(vessels loss and neovascularization) of mouse model of oxygen-induced retinopathy, which
may provide a valubale therapeutic tool for ischemic-induced retinal diseases.
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I. Introduction
Retinopathy of prematurity (ROP) is a vessel-prolifera-
tive disorder of the retina primarily affecting premature
infants. New vessel formation in ROP causes preventable
blindness in children and diabetic retinopathy causes visual
loss with vitreous hemorrhage, retinal detachment, and
neovascular glaucoma [35, 36]. In the murine model, there
are two phases in the ROP pathological process. In the first
phase, hyperoxia induces cessation of normal vessel growth
and regression of existing vessels, subsequently, causing
obliteration of normal retinal vessels. VEGF is essential in
the development of the normal retinal vasculature, but
supplemental oxygen interferes with normal VEGF driven
vascular development. During this phase, hyperoxia sup-
presses VEGF expression, resulting in the loss of the physi-
ological wave of VEGF anterior to the growing vascular
front [41], hyperoxia-induced vaso-obliteration is caused by
apoptosis of vascular endothelial cells and can be partially
prevented by administration of exogenous VEGF or PIGF-1,
a VEGFR-1 specific ligand [2, 42, 44]. Besides, IGF-1 is
critical in the first phase of ROP. IGF-1 controls maximum
VEGF activation of the Akt endothelial cell survival path-
way and the loss of IGF-1 expression could cause ROP by
preventing the normal survival of vascular endothelial cells
[20]. In the second phase, along with hyperoxia-induced
vessel loss and subsequent relative hypoxia, the overexpres-
sion of pro-angiogenic substances including VEGF, angio-
poietin, NO, EPO, IGF-1, TNF, etc., causes the development
of retinal neovascularization, which is thought to occur in
response to ischemic and hypoxic insult [12], which leads
to alterations in the existing vasculature and compensatory,
albeit pathological, new capillary growth [17, 29]. That isWang et al. 104
to say, the insufficient blood supply resulting from early
vessel loss causes tissue ischemia and hypoxia, which deter-
mines the severity of subsequent pathological retinal vessel
growth. As the basic treatment for retinal neovasculariza-
tion, laser photocoagulation cannot prevent progression of
this aberrant angiogenesis and usually causes inflammation
and tissue destruction [4].
Akt, also named protein kinase B, is activated by a
number of growth factors and cytokines, and serves as a
multifunctional regulator of cell biology, glucose metabo-
lism and protein synthesis [13, 21, 22]. Furthermore, several
lines of evidence suggest a link between Akt and neo-
vascularization. Endothelial nitric oxide synthase (eNOS) is
a known downstream target of Akt, which has recently been
shown to phosphorylate eNOS, leading to persistent activa-
tion [31], and contribute to postnatal neovascularization [1,
37, 39]. Moreover, recent studies suggest that Akt is known
to mediate hypoxia-induced expression of VEGF in vitro
and in vivo [3, 32], and the VEGF-induced endothelial cell
migration requires the activation of Akt [8]. Akt involved in
antiapoptosis signaling and is sufficient to promote survival
of endothelial cells [16]. Numerous studies have demon-
strated in various cell types that constitutive activation of
Akt signaling is sufficient to block cell death induced
by a variety of apoptotic stimuli and that transduction of
dominant-negative Akt inhibits growth factor induced cell
survival [11, 14, 15, 50]. On the whole, Akt kinases, as a
“master switch”, control essential cellular functions, includ-
ing proliferation, apoptosis, metabolism, and transcription,
and have been considered as promising targets for treatment
of pathological angiogenesis such as cancer and ischemic
injury [5].
In this study, we sought to detect the expressions of
Akt in the animal model of oxygen-induced retinopathy, and
to investigate the role of Akt on suppressing experimental
vessel loss and retinal neovascularization in this model.
II. Materials and Methods
Animal model of proliferative retinopathy
We certify that all applicable institutional and gov-
ernmental regulations concerning the ethical use of
animals were followed during this research. A reproducible
model of oxygen-induced retinal neovascularization has
been described previously in detail [46]. Briefly, seven-
day-old C57BL/6J (P7) mice (Laboratory Animal Center of
Central South University) were exposed to 75%±2% oxygen
(hyperoxia) for 5 days with the nursing mothers and then
returned to room air for 5 days, producing retinal ischemia
and neovascularization by P17. Mice of the same strain and
of the same age were kept in room air and used as normoxia
controls.
Western blot analysis
The mouse retinas were collected and lysed in lysis
buffer (20 mM Tris, pH 7.4; 150 mM NaCl; 1 mM ethyl-
enediamine tetraacetic acid; 1 mM orthovanadate; 1 mM
phenylmethylsulfonyl fluoride; 1 μg/ml leupeptin; 10 μg/
ml aprotinin) containing protease inhibitors (Boehringer,
Mannheim, Germany). After homogenization and centrifu-
gation, the supernatant was collected for total protein values.
The amount of protein was determined with the BCA protein
assay kit (Sigma-Aldrich Chemical Co., St Louis, MO,
USA). The total protein (40 μg per lane) from each sample
was loaded on sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) using a 10% Tris-glycine gel
(Invitrogen, Paisley, UK) and transferred onto a PVDF
membrane (Pierce Co, Rockford, USA) at 300 mA for 1 hr.
Antibody reaction was performed after blocking of non-
specific binding sites with 5% skim milk. The membrane
was incubated with goat polyclonal anti-Akt antibody and
anti-pAkt antibody (1:1000 dilution; Cell Signaling Tech-
nology Inc, Danvers, MA) overnight at 4°C, followed by
incubation with horseradish peroxidase-conjugated second-
ary antibody (goat anti-rabbit antibody; Bytime, Haimen,
China) for 2 hr at room temperature. Peroxidase activity on
PVDF membranes was visualized on X-ray film by means of
the ECL Western blotting detection system (Amersham
Pharmacia Biotech, Piscataway, NJ, USA). Experiments
were repeated 3 times.
RNA extraction and RT-PCR
Eyeballs were enucleated from the mice at P17, and
the retinas were separated from eyeballs. The whole RNA
of murine retinas were isolated with TRIzol reagent
(Invitrogen, Paisley, UK) according to the manufacturer’s
instructions. Each RNA extract (2 mg) was reverse-
transcribed into cDNA using RevertAidTM First Strand
cDNA Synthesis Kit (Mbi, Glen Burnie, MD, USA). PCR
was performed in 50 μl of a solution containing Taq DNA
polymerase, dNTP, RT products, Akt primer and GAPDH
primer. To amplify Akt in the murine retinas, the primer pair
5-TGGACTTCCGATCAGGCTCAC-3 (sense) and 5-GCC
CTTGCCCAGTAGCTTCA-3 (antisense) were used to gen-
erate 125 bp PCR product. The primer pair 5-AAGCCCAT
CACCATCTTCCA-3 (sense) and 5-CCTGCTTCACCACC
TTCTTG-3 (antisense) were designed to generate 580 bp
PCR product of murine GAPDH.
After pre-incubation for 5 min at 94°C, 35 cycles of
amplification (94°C for 30 sec, 55°C for 30 sec, and 72°C
for 30 sec) were performed. Amplified products were run
in a 1.5% ethidium bromide agarose gel, band intensities
were captured with a ChemiDoc system and LabWorks
software (UVP, Upland, CA, USA), and values were trans-
ferred to an Excel spreadsheet for calculation of means and
standard errors.
Angiography with high-molecular-weight fluorescein-
dextran
Mice were deeply anesthetized by intraperitoneal pento-
barbital sodium and sacrificed by intracardiac perfusion with
PBS containing 1 ml of 50 mg/ml FITC-dextran (molecular
weight 2,000,000, Sigma-Aldrich Chemical Co. St Louis,
MO, USA). Subsequently, the eyes were enucleated and fixedAkt Promotes Formation of Neovascularization 105
Fig. 1. RT-PCR and Western blot analysis for Akt or phosphorylated Akt in the retinas of experimental animals. The bands of mRNA or protein
expression were measured by densitometry with Quantity One quantitation analysis software package. (A) The expression of Akt mRNA in the
first phase (P7, P9, and P11) under normoxia or hyperoxia conditions and the relative Akt mRNA quantification related to GAPDH.
Means±SEM of mRNA level normalized to GAPDH (internal control) were calculated. Statistical significance was determined by Student’s
t-test (*p<0.05). (B) The expression of Akt mRNA in the second phase (P12, P14, P16, P17, P23) under normoxia or hypoxia conditions and the
relative Akt mRNA quantification related to GAPDH. Means±SEM of mRNA level normalized to GAPDH (internal control) were calculated.
Statistical significance was determined by Student’s t-test (*p<0.01). (C) The expression of Akt and p-Akt protein in the first phase (P7, P9,
P11) under normoxia or hyperoxia conditions and the relative Akt or p-Akt protein quantification related to β-actin. Means±SEM of Akt or
p-Akt protein level normalized to β-actin (internal control) were calculated. Statistical significance was determined by Student’s t test (*p<0.01,
**p<0.01). (D) The expression of Akt and p-Akt protein second phase (P12, P14, P16, P17, and P23) under normoxia or hypoxia conditions and
the relative Akt or p-Akt protein quantification related to β-actin. Means±SEM of Akt or p-Akt protein level normalized to β-actin (internal
control) were calculated. Statistical significance was determined by Student’s t test (*p<0.05, **p<0.05).Wang et al. 106
in 4% paraformaldehyde for 1 hr at room temperature. The
retinas were dissected and flat mounted on microscope
slides with glycerol gelatin. Images of each of the 4 quad-
rants of whole mounted retina were taken at ×5 magnifica-
tions on a Leica DMI 4000B confocal microscope (Wetzlar,
Germany) and imported into Adobe Photoshop software.
Retinal segments were merged to produce an image of the
entire retina.
Histologic quantitation of retinal neovascularization
Mice were killed by IP injections of an overdose of
sodium pentobarbital. Their eyes were enucleated, fixed
with 4% paraformaldehyde in PBS, and embedded in
paraffin. A series of 6-μm paraffin-embedded axial retinal
sections were obtained starting at the optic nerve head and
the sections were stained with hematoxylin and eosin. An
individual blinded to the treatment groups examined the
sections for evidence of neovascularization via light micros-
copy. Neovascularization was quantified by the number of
retinal vascular endothelial cell nuclei anterior to the inner
limiting membrane (ILM). Counts were performed in trans-
verse sections through the center of the eye. Averaging of
the 10 counted sections yielded a mean number of neo-
vascular cell nuclei per section per eye [24, 48].
Recombinant Akt and Akt inhibitor intravitreal injections
For evaluation of vessel loss, at P6 and P7, mice were
anesthetized with intraperitoneal injection of pentobarbital
sodium. The lid fissure was opened using a No11 scalpel
blade and the eye was proptosed. Intravitreal injections
Fig. 1 (continued)Akt Promotes Formation of Neovascularization 107
were performed by first entering the eye with an Ethicon
TG140-8 suture needle at the posterior limbus. A 32-gauge
Hamilton needle and syringe were used to deliver 1 μl
recombinant Akt (Abnova Taiwan Corporation, Taipei City,
Taiwan) into the vitreous cavity. Control PBS was injected
into littermates. The eye was then repositioned and the lids
were approximated over the cornea. After oxygen exposure,
eyes from P8 mice were perfused with FITC-dextran.
For evaluation of neovascularization, at P12, accord-
ing to the same method, 1.5 μl Akt inhibitor (1L-6-hy-
droxymethyl-chiro-inositol2-(R)-2-O-methyl-3-Ooctadecyl-
carbonate. Merck Chemicals Ltd, Darmstadt, Germany)
were injected into vitreous cavity. Control PBS was injected
into littermates. Retinal neovascularization was analyzed
with FITC-dextran and histological analysis at P17.
Statistics
The results were given as mean±SEM. One-way
ANOVA followed by the LSD t-test was used to evaluate
significant differences. A p value<0.05 was considered
statistically significant.
III. Results
Akt mRNA expression and Akt, p-Akt protein expression 
during oxygen-induced retinopathy
Retinal Akt mRNA, retinal Akt and p-Akt protein
expression was greatly suppressed (Fig. 1A, C) during
hyperoxia treatment (P7 to P12), when oxygen-induced reti-
nal vessel loss occurs. After returning to room air, hypoxia
induces retinal neovascularization (P12 to P17). During the
relative hypoxic phase, retinal Akt mRNA, Akt and pAkt
protein were increased dramatically (Fig. 1B, D). No sig-
nificant differences were found in normoxia groups. These
data suggest that lack of Akt in the first phase might con-
tribute to early vessel loss and the onset of retinopathy,
while the increase of Akt in the second phase might play a
role in neovascularization.
Use of exogenous Akt in the first phase can prevents retinal 
vessel loss
We next examined whether exogenous Akt treatment
during the first phase of oxygen-induced retinopathy (when
retinal Akt levels are suppressed) helps to prevent retinal
vessel loss. At P8, mice treated with recombinant Akt
had a capillary-free/total retinal area of 13.0%±0.8% com-
pared with 31.4%±0.3% in PBS-injected littermate controls
(P≤0.001; Fig. 2A, B), suggesting recombinant Akt treat-
ment had a protective effect. These data demonstrate that
correcting retinal Akt deficiency during the first phase of
retinopathy with exogenous Akt protects the postnatal
mouse retina from hyperoxia-induced vessel loss.
Use of Akt inhibitor in the second phase can prevent retinal 
neovascularization, but cannot prevents retinal vessel loss
In order to assess the role of Akt inhibitor function
in retinal angiogenesis, we next explored whether late treat-
ment with Akt inhibitor to prevent pathological angiogenesis
in the second phase of retinopathy. Retinal neovasculariza-
tion was also evaluated by measuring the neovascular
Fig. 2. Recombinant Akt treatment suppressed retinal
vessel loss in a murine oxygen-induced retinopathy
model. (A) Representative retinal whole-mounts
showing area of capillary-free after 24 hr of oxygen
exposure and intraperitoneal injections (P6 and P7)
of recombinant Akt and PBS. Areas of capillary
(gray) were quantified. Original magnification ×5.
(B) The capillary-free areas and the total areas were
quantified. Data are shown as mean±SEM. (PBS,
n=10; recombinant Akt, n=15; ***P≤0.001).Wang et al. 108
tufts area and histological analysis. At P17, mice treated late
with Akt inhibitor during the second phase had a pathologic
neovascular tufts (6.0%±0.4%) compared with PBS control
(14.0%±0.8%; P≤0.001; Fig. 3A, B). The histological
analysis shows that the average numbers of neovascular
cell nuclei were 51.0±5.0 in eyes injected with PBS (n=10),
and 17.0±3.0 in eyes injected with Akt inhibitor (n=15).
There was a significant reduction of neovascular nuclei
following local delivery of Akt inhibitor in the mouse OIR
model (Fig. 3D, E, P≤0.001). For the area of capillary-free,
which was caused by centering on the optic nerve, no differ-
ences were seen in capillary-free area between Akt inhibitor
and PBS treatments (Akt 21.3%±0.5% compared with PBS
22.5%±0.8%). Our data suggest that Akt inhibitor treatment
during the second phase of retinopathy protects the retina
from vessel pathological proliferation, but cannot protect the
retina from vessel loss.
Fig. 3. Akt inhibitor treatment suppressed retinal neovascularization but not vessel loss in the murine oxygen-induced retinopathy model. (A)
Representative retinal whole-mounts showing area of capillary-free and neovascularization after 5 days of relative oxygen deficiency exposure
and intravitreal injections (P12) of Akt inhibitor and PBS. Areas of capillary (gray) and neovascularization (pink) were quantified. Original
magnification ×5. (B) The areas of neovascularization and the total areas were quantified. Data are shown as mean±SEM. (PBS, n=10; recom-
binant Akt, n=15; ***P≤0.001). (C) The capillary-free areas and the total areas were quantified. (D) Histologic sections of P17 retina from
PBS-treated (left) and Akt inhibitor-treated (right) eyes of mouse exposed to hyperoxia. Extensive preretinal neovascular tufts were apparent
(arrow). (E) The number of neovascular nuclei anterior to the ILM in 6-μm retinal sections was quantified. (PBS, n=10; recombinant Akt, n=15;
***P≤0.001).Akt Promotes Formation of Neovascularization 109
IV. Discussion
The focus of the current study is to test the effects of
Akt in preventing retinal vessel loss and neovascularization
in vivo. Our results show that Akt presents a dynamic ex-
pression during the whole process of oxygen-induced reti-
nopathy in the animal model. Early use of recombinant Akt
can prevents retinal vessel loss and the late use of Akt
inhibitor can apparently inhibits retinal neovascularization
in mice.
In the first phase of oxygen-induced retinopathy,
hyperoxia-induced vessel loss is caused by apoptosis of
vascular endothelial cells, and also hyperoxia suppresses
VEGF expression [32] and IGF-1 levels [20]. In our studies,
we also found that Akt mRNA, Akt and p-Akt expression
was greatly suppressed under hyperoxia environment. These
data suggest that lack of Akt in the first phase might con-
tribute to early vessel loss and the onset of retinopathy.
In view of the antiapotosis effects of Akt, we next treated
model mouse with early use of recombinant Akt. It helps
prevent the vessel loss and ischemia, thereby suppressing
subsequent retinal neovascularization. Early use of Akt
protects the retina from hyperoxia-induced vessel loss,
which is consistent with previous studies that have found
that activated Akt protects the lung from oxidant-induced
injury and delays death of mice [30]. These findings suggest
the important possibility of treating retinopathy patients
early with Akt in order to prevent retinal ischemia without
provoking neovascularization.
In addition, late inhibiting Akt alone during the neo-
vascularization phase of retinopathy does protect retinal
vasculature, and could decrease the formation of neo-
vascularization dramatically, but the normal total retinal
vascular area was not significantly changed. The second
phase of ROP is characterized by hypoxia-induced retinal
neovascularization. These leaky vessels can lead to retinal
detachment and blindness. In this phase, we found that Akt
mRNA, Akt and p-Akt expression are elevated, which con-
tribute to pathological retinal angiogenesis. Administering
Akt inhibitor to these patients could suppress the retinal
neovascularization. Akt plays a very central role in pro-
moting the survival of a wide range of cell types [50], and
several studies indicate that Akt activation plays an impor-
tant role in inhibiting cell apoptosis in fibroblasts, epithelial
and lymphoid cell lines, and neuronal cells [28]. In ECs,
the majority of growth factor-induced responses are medi-
ated by the activation of the Akt signaling pathway [45].
Vascular endothelial growth factor (VEGF) displays multi-
ple biological activities in endothelial cells, including the
enhancement of retinal endothelial cell survival [2]. In
addition, it was also shown that several other stimuli includ-
ing insulin-like growth factor-I (IGF-I) [33], insulin [23],
angiopoietin-1 (Ang-1) [40], hepatocyte growth factor [38],
the small proteoglycan decorin [43], fluid shear stress [46],
sphingosine-1-phosphate (S1P) [26], estrogen [34], reactive
oxygen species [47], and corticosteroids [19] also activate
Akt signaling, illustrating the central role of this pathway
in controlling endothelial cell viability. Blocking of Akt
pathway also can effectively inhibit retinal endothelial cell
survival and migration induced by VEGF in vitro [49].
Moreover, shear stress and insulin could inhibit endothelial
cell apoptosis by activating Akt [6, 23]. Thus, activation of
Akt seems to be a general antiapoptotic mechanism induced
by proangiogenic stimuli. Because apoptosis of endothelial
cells can against angiogenesis, we speculate that the Akt
signaling pathway leading to apoptosis suppression may
significantly contribute to angiogenesis, a process required
for the revascularization of ischemic tissue. Akt signaling
is important for normal vascular development, since deple-
tion of Akt leads to angiogenic defects [5], Akt is expressed
in the retina suggesting that it is an endogenous retinal
survival factor, and that the Akt pathway can increase endo-
thelial cell proliferation and protect vasculature counteract
ischemia and apoptosis. Akt and p-Akt are present in retinal
vessels. Therefore they may be activated locally to promote
retinal cell survival.
Apart from the mature ECs, many studies have also
been done on the regulation of the EPCs biology by Akt.
The study by Grant et al. indicates that adult hematopoietic
stem cells can clonally differentiate into all hematopoietic
cell lineages as well as endothelial cells that revascularize
the adult retina. They also show that recruitment of endo-
thelial precursors to sites of ischemic injury has a significant
role in retinal neovascularization [18]. Recent studies re-
vealed that statins requires activation of the PI3K/Akt
pathway to augment EPC differentiation and promote neo-
vascularization, suggesting a common mechanism and an
essential role for Akt in regulating hematopoietic stem cell
differentiation [9, 10, 27]. Subsequently, it is not only
demonstrated that Akt regulates differentiation of EPCs,
but also considered that Akt can be used as a target to
modify EPCs kinetics [7]. Furthermore, Akt can modulate
the trafficking of EPCs in ischemic muscle [25], and Akt
knockout mice have reduced EPCs mobilization in response
to limb ischemia [1].
In summary, we have shown that recombinant Akt
has potent inhibitory effects on the vessel loss and the sub-
sequent development of retinal neovascularization, and that
the Akt inhibitor has dramatic effects on inhibiting retinal
neovascularization alone in vivo. Local treatment can pro-
duce less toxicity than systemic delivery, so we chosed to
deliver recombinant Akt and Akt inhibitor via intravitreal
injection in order to limit side effects that might appear
after systemic delivery. We did not observe the toxicity of
recombinant Akt and Akt inhibitor in this study. These
data suggest that targeting Akt function could provide a
novel approach for treatment of angiogenesis in retinal
neovascularization diseases.
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